Biomarin Pharmaceutical Inc (BMRN)

96.22
1.25 1.32
NASDAQ : Health Care
Prev Close 94.97
Open 95.09
Day Low/High 94.42 / 96.36
52 Wk Low/High 62.12 / 136.85
Volume 1.29M
Avg Volume 1.95M
Exchange NASDAQ
Shares Outstanding 163.47M
Market Cap 15.55B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Facebook Stands Out and FormFactor Has a Good Start

Facebook Stands Out and FormFactor Has a Good Start

Overall, this is still a good environment for stock picking.

Cramer: Companies Are Issuing a Lot of Paper

Cramer: Companies Are Issuing a Lot of Paper

They're striking while the iron is hottest to raise money, reduce debt.

BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering

BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering

BioMarin (BMRN) stock is trading lower after the market close after announcing a public offering of common stock.

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Cramer: 11 Reasons Why the Market Turned

Cramer: 11 Reasons Why the Market Turned

All of these add up to a level of insecurity on the part of sidelined money.

Biomarin Pharmaceutical (BMRN) Highlighted As Storm The Castle Stock

Biomarin Pharmaceutical (BMRN) Highlighted As Storm The Castle Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.

BioMarin (BMRN) Stock Soars on Takeover Speculation

BioMarin (BMRN) Stock Soars on Takeover Speculation

BioMarin (BMRN) stock is trading sharply higher this morning following reports that Roche (RHHBY) could pursue a takeover.

Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open

Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a pre-market mover with heavy volume candidate

Medivation Tries to Prove Its Worth

Medivation Tries to Prove Its Worth

A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

The U.S. woke up today to the news of a "Brexit" win, which has sent global markets reeling.

BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL

BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL

Investor event to be held in Orlando following the July 27 oral presentation at the WFH meeting

BioMarin Pharmaceuticals Jumps on Takeover Talk

BioMarin Pharmaceuticals Jumps on Takeover Talk

Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.